echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > To Biao Qilu!

    To Biao Qilu!

    • Last Update: 2021-03-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Medical Network News on March 8 Recently, Jiangsu Haosen Pharmaceutical has reported frequent successes, following the first review of Decitabine for injection.
    On March 3, the official website of the State Food and Drug Administration showed that Jiangsu Haosen Pharmaceutical's vinorelbine tartrate injection was approved as a supplementary application.
    Prior to this, vinorelbine tartrate injection had not been reviewed by companies.
    According to data from Minai.
    com, the supplementary application for consistency evaluation of vinorelbine tartrate injection of Qilu Pharmaceutical (Hainan) is currently under review and approval.
     
    March 3, 2021 Drug approval certificate pending information release
     
    Vinorelbine tartrate injection is used for non-small cell lung cancer, metastatic breast cancer, advanced ovarian cancer, malignant lymphoma, etc.
     
     
     Source: One-click search on Mi Nei.
    com
     
    According to data from Menet.
    com, in recent years , the sales of Changchun Ruibin injections in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have exceeded 100 million yuan.
    The growth rate in the first half of 2020 will be more than 100 million yuan.
    The decline.
    Among them, Jiangsu Hausen Pharmaceutical has the largest market share, exceeding 70%.
    There are 9 manufacturers of vinorelbine tartrate injection, including Jiangsu Haosen Pharmaceutical, Qilu Pharmaceutical (Hainan), and Beijing Shuanglu Pharmaceutical.
     
      
    Source: MED2.
    0 Chinese Drug Evaluation Database
     
      In terms of consistency evaluation, the supplementary application for consistency evaluation of vinorelbine tartrate injection of Qilu Pharmaceutical (Hainan) is currently under review and approval.
     
      Source: official website of the State Food and Drug Administration, Mi Nei.
    com database
      Medical Network News on March 8 Recently, Jiangsu Haosen Pharmaceutical has reported frequent successes, following the first review of Decitabine for injection.
    On March 3, the official website of the State Food and Drug Administration showed that Jiangsu Haosen Pharmaceutical's vinorelbine tartrate injection was approved as a supplementary application.
    Prior to this, vinorelbine tartrate injection had not been reviewed by companies.
    According to data from Minai.
    com, the supplementary application for consistency evaluation of vinorelbine tartrate injection of Qilu Pharmaceutical (Hainan) is currently under review and approval.
     
      March 3, 2021 Drug approval certificate pending information release
     
      Vinorelbine tartrate injection is used for non-small cell lung cancer, metastatic breast cancer, advanced ovarian cancer, malignant lymphoma, etc.
     
     
     Source: One-click search on Mi Nei.
    com
     
      According to data from Menet.
    com, in recent years , the sales of Changchun Ruibin injections in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have exceeded 100 million yuan.
    The growth rate in the first half of 2020 will be more than 100 million yuan.
    The decline.
    Among them, Jiangsu Hausen Pharmaceutical has the largest market share, exceeding 70%.
    There are 9 manufacturers of vinorelbine tartrate injection, including Jiangsu Haosen Pharmaceutical, Qilu Pharmaceutical (Hainan), and Beijing Shuanglu Pharmaceutical.
     
      
    Source: MED2.
    0 Chinese Drug Evaluation Database
     
      In terms of consistency evaluation, the supplementary application for consistency evaluation of vinorelbine tartrate injection of Qilu Pharmaceutical (Hainan) is currently under review and approval.
     
      Source: official website of the State Food and Drug Administration, Mi Nei.
    com database
      Medical Network News on March 8 Recently, Jiangsu Haosen Pharmaceutical has reported frequent successes, following the first review of Decitabine for injection.
    On March 3, the official website of the State Food and Drug Administration showed that Jiangsu Haosen Pharmaceutical's vinorelbine tartrate injection was approved as a supplementary application.
    Prior to this, vinorelbine tartrate injection had not been reviewed by companies.
    According to data from Minai.
    com, the supplementary application for consistency evaluation of vinorelbine tartrate injection of Qilu Pharmaceutical (Hainan) is currently under review and approval.
     
      March 3, 2021 Drug approval certificate pending information release
     
      Vinorelbine tartrate injection is used for non-small cell lung cancer, metastatic breast cancer, advanced ovarian cancer, malignant lymphoma, etc.
     
     
     Source: One-click search on Mi Nei.
    com
     
      According to data from Menet.
    com, in recent years , the sales of Changchun Ruibin injections in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have exceeded 100 million yuan.
    The growth rate in the first half of 2020 will be more than 100 million yuan.
    The decline.
    Among them, Jiangsu Hausen Pharmaceutical has the largest market share, exceeding 70%.
    There are 9 manufacturers of vinorelbine tartrate injection, including Jiangsu Haosen Pharmaceutical, Qilu Pharmaceutical (Hainan), and Beijing Shuanglu Pharmaceutical.
    Hospital hospital hospital
     
      
    Source: MED2.
    0 Chinese Drug Evaluation Database
     
      In terms of consistency evaluation, the supplementary application for consistency evaluation of vinorelbine tartrate injection of Qilu Pharmaceutical (Hainan) is currently under review and approval.
     
      Source: official website of the State Food and Drug Administration, Mi Nei.
    com database
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.